Latest Commercialisation News

Page 125 of 189
Starpharma has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year, reinforcing its commitment to advancing dendrimer technology and biotechnology innovation in Australia.
Ada Torres
Ada Torres
28 Aug 2025
Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.
Ada Torres
Ada Torres
28 Aug 2025
dorsaVi appoints Mathew Regan as Group CEO to spearhead commercialisation of next-gen RRAM-enabled AI and robotics technologies, aiming for global expansion.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.
Ada Torres
Ada Torres
28 Aug 2025
Dimerix Limited reported a 22% reduction in its FY2025 loss to $13.25 million, driven by strong licensing revenues and advancing its pivotal Phase 3 clinical trial for DMX-200. The company secured new global partnerships valued at up to AU$1.4 billion, bolstering its cash reserves and commercial prospects.
Ada Torres
Ada Torres
28 Aug 2025
Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.
Ada Torres
Ada Torres
28 Aug 2025
Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.
Victor Sage
Victor Sage
28 Aug 2025
Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.
Ada Torres
Ada Torres
28 Aug 2025
AnteoTech Ltd reports a strong FY2025 with doubled sales revenue, strategic partnerships, and key product milestones in battery materials and life sciences diagnostics.
Maxwell Dee
Maxwell Dee
28 Aug 2025
Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.
Ada Torres
Ada Torres
28 Aug 2025
Weebit Nano Limited reported a strong FY25 with revenues surging over fourfold to $4.4 million and a narrowed net loss of $38.4 million, driven by key licensing deals and progress towards automotive-grade ReRAM qualification.
Sophie Babbage
Sophie Babbage
28 Aug 2025
CurveBeam AI Limited posted a strong 85% increase in revenue to $12.1 million for FY25, alongside a reduced net loss of $16.8 million. Despite operational improvements and a recent $11.58 million capital raise, the company flags material uncertainty over its ability to continue as a going concern.
Ada Torres
Ada Torres
28 Aug 2025